Edding

Executive Summary

Edding (Eddingpharm) is a private Chinese biotech company headquartered in Shanghai, founded in 2010, specializing in antibody-based therapies for oncology and immunology. With a focus on discovering and engineering novel monoclonal and bispecific antibodies, the company aims to address autoimmune diseases and cancer through innovative biologic approaches. Currently in the preclinical stage, Edding has developed a pipeline of candidates targeting key pathways in immuno-oncology and autoimmune disorders. The company employs between 50 and 200 staff and has not yet disclosed total funding or valuation, indicating it may be in an early growth phase relying on private investments. Given its preclinical status, Edding is likely nearing key inflection points such as Investigational New Drug (IND) filings or first-in-human studies, which could unlock value and attract partnership interest. The biotech sector in China continues to evolve rapidly, and Edding's focus on differentiated antibody formats positions it within a competitive but promising landscape.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Oncology Candidate40% success
• Q4 2026In-licensing or Partnership Deal for Autoimmune Asset35% success
• H2 2026Series B or C Funding Round50% success